Anti-PLA2R antibodies: implications for therapeutic planning and the prediction of remission in membranous nephropathy
Open Access
- 1 June 2026
- journal article
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 48 (2) , e2026E009
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Anti-PLA2R antibody reduction as a predictor of treatment response in primary membranous nephropathy: a retrospective studyBrazilian Journal of Nephrology, 2026
- Identification of early predictors of clinical remission in primary membranous nephropathy: a post hoc analysis of the STARMEN trialClinical Kidney Journal, 2025
- KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular DiseasesKidney International, 2021
- Autoantibodies against phospholipase A2 receptor in Brazilian patients with glomerular diseasesInternational Urology and Nephrology, 2020
- Corrigendum: Autoantibodies in renal diseases – clinical significance and recent developments in serological detectionFrontiers in Immunology, 2020
- Serum anti-PLA2R antibody as a diagnostic biomarker of idiopathic membranous nephropathy: The optimal cut-off value for Chinese patientsClinica Chimica Acta, 2018